Inventors with similar research interests:
Location History:
- Willowdale, CA (1992 - 2007)
- Toronto, CA (2002 - 2010)
Company Filing History:
96 out of 145 
45 out of 75 
14 out of 163 
Years Active: 1992-2010
Areas of Expertise:
Title: Michel Henri Klein - A Brillant Inventor's Journey
Introduction:
Michel Henri Klein is a prolific inventor based in Willowdale, CA, known for his remarkable contributions in the field of biotechnology and immunology. With an impressive portfolio of 142 patents, Klein has made significant breakthroughs in recombinant protein production and the development of chimeric immunogens. This article aims to delve into his latest patents, career highlights, collaborations, and shed light on his remarkable journey as an innovator.
Latest Patents:
Among his latest patents, two notable ones stand out: "Recombinant production of Hia protein" and "Chimeric immunogens." In the first patent, Klein describes a method for producing Hia protein, in both full-length and N-terminally truncated forms, from non-typeable strains. The patent also encompasses the nucleic acid and deduced amino acid sequences of Hia genes from various non-typeable and typeable strains. This breakthrough offers potential applications in the development of vaccines and therapeutic interventions.
In the second patent, Klein showcases his ingenuity again by introducing multimeric hybrid genes encoding chimeric proteins. These genes combine antigenic regions of proteins from different pathogens, specifically parainfluenza virus (PIV) and respiratory syncytial virus (RSV). The resulting recombinant immunogen offers promising possibilities in protecting infants and vulnerable individuals against both PIV and RSV-related diseases.
Career Highlights:
Throughout his illustrious career, Michel Henri Klein has worked with renowned companies at the forefront of biotechnology. He spent considerable time at Connaught Laboratories Limited, a biopharmaceutical company known for its pioneering work in vaccine development. Klein's association with Connaught Laboratories Limited underscores his commitment to advancing immunological concepts from the laboratory to practical application, fostering better public health outcomes.
Following his success at Connaught, Klein took his expertise to Aventis Pasteur Limited. Aventis Pasteur Limited, a global leader in vaccines, provided Klein with an excellent platform to further hone his skills and make groundbreaking contributions in the field of immunology. His work at Aventis Pasteur Limited undoubtedly played a critical role in advancing vaccine technologies and improving global health initiatives.
Collaborations:
In his quest for innovation, Michel Henri Klein has collaborated with esteemed colleagues, further enhancing his contributions. Working closely with esteemed scientists like Sheena M Loosmore and Pele Chong, Klein has cultivated an environment of collaboration and knowledge sharing. These productive collaborations have led to the development of novel approaches and expanded the scope of their work, bringing innovative solutions to complex problems.
Conclusion:
Michel Henri Klein's inventive spirit and dedication to the field of biotechnology and immunology have resulted in numerous patent successes. His breakthroughs in recombinant protein production and the development of chimeric immunogens have great potential for applications in medicine and public health. With an impressive portfolio of 142 patents, Klein's career highlights at Connaught Laboratories Limited and Aventis Pasteur Limited demonstrate his commitment to advancing vaccine technologies and improving global health outcomes. Through collaborations with fellow experts, Klein has cultivated an environment of innovation and discovery, further solidifying his contributions to the scientific community.